Patents Assigned to Akinion Pharmaceuticals AB
  • Publication number: 20130203774
    Abstract: The present invention relates to compounds of the general formula (I) wherein R1, R2 and R3 are as defined herein, which can act as inhibitors of protein kinases, specially the Fms-like tyrosine kinase 3 (FLT3). The invention also relates to the use of the compounds in therapy, pharmaceutical compositions comprising the compounds and the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of hematological malignancies, such as AML, MLL, T-ALL, B-ALL and CMML, myeloproliferative disorders, other proliferative disorders like cancer, autoimmune disorders and skin disorders like psoriasis and atopic dermatitis.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 8, 2013
    Applicant: AKINION PHARMACEUTICALS AB
    Inventor: AKINION PHARMACEUTICALS AB
  • Patent number: 8436171
    Abstract: The present invention relates to compounds of the general formula (I) wherein R1, R2 and R3 are as defined herein, which can act as inhibitors of protein kinases, specially the Fms-like tyrosine kinase 3 (FLT3). A species illustrative of members of the general formula is The invention also relates to the use of the compounds in therapy, pharmaceutical compositions comprising the compounds and the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of hematological malignancies, such as AML, MLL, T-ALL, B-ALL and CMML, myeloproliferative disorders, other proliferative disorders like cancer, autoimmune disorders and skin disorders like psoriasis and atopic dermatitis.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: May 7, 2013
    Assignee: Akinion Pharmaceuticals AB
    Inventors: Annika Jenmalm Jensen, Fredrik Lehmann, Erik Nordling, Vendela Parrow